Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee

Phase 3. Efficacy of Flavocoxid Compared With Naproxen in Subjects With Moderate-severe Osteoarthritis (OA) of the Knee

To compare flavocoxid with naproxen for patients with moderate to severe osteoarthritis of the knee.

Study Overview

• Status: Completed
• Conditions: Osteoarthritis of Knee
• Intervention / Treatment: Dietary supplement: flavocoxid; Drug: Naproxen

Detailed Description

Efficacy of flavocoxid 500 mg compared with naproxen 500 mg in subjects with moderate-severe osteoarthritis of the knee.

• Study Type: Interventional
• Enrollment (Actual): 223
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Willing and able to read and understand informed consent and questionnaires in English.
• Adults of either gender age 35-75 years, in general good health.
• Established X-ray diagnosis of osteoarthritis of at least one knee.
• Taken NSAID including COX-2 (cyclo-oxygenase-2) inhibitor in full therapeutic dose for at least one month prior to screening.
• Able and will to discontinue osteoarthritis medications until flare criteria met.
• BMI</= 45
• Subjects must rate target knee at least 5 out of 10 on discomfort VAS (visual analogue scale) at baseline visit.
• Have an increase of at least 15mm on a 100mm pain VAS (visual analogue scale) from screening to baseline visit.
• Must use acceptable birth control if female.
• Screening fecal occult must be negative.
• Able to attend all required visits
• Physical Therapy is allowed as long as the type and frequency remains unchanged for the duration of the study.

Exclusion Criteria:

• Refusal to sign consent.
• Inability to attend all clinic visits
• Grade 0-1 K-L changes in both knees or grade 4 K-L changes in either knee on standing A/P radiograph
• Pregnant or lactating women
• History of serious cardio-vascular disease.
• Recurrent arrythmias, except paroxysmal tachycardia, cardiomyopathy, myocardial infarct within one year of screening.
• History of chronic esophageal, gastric or duodenal disease
• History of upper GI bleeding within the past 2 years.
• Any GI disorder associated with malabsorption
• Any musculo-skeletal or neurological condition that results in pain or gait disturbance that might confound evaluation of target knee.
• Uncontrolled Diabetes Mellitus
• History of bleeding disorder or concurrent use of coumadin or any agent used to reduce blood clotting or platelet adhesiveness.
• Concurrent use of any anti-arthritic medication, including corticosteroids regardless of the reason for use. (low dose aspirin for cardioprotection is allowed)
• History of chronic renal disease with creatinine >2.0 or nephrotic syndrome with 24 hour protein excretion >1000mg.
• Intra-articular injection of any hyaluronic acid preparation in the target knee joint within 4 months of baseline visit.
• Intra-articular injection of a corticosteroid in the target knee joint within 2 months of the baseline visit.
• BMI>45
• History of allergic reaction to flavonoid or flavan containing foods or products (example: red wine, colored fruits and vegetable, brazil nuts, tea, natto)
• History of allergy to aspirin, naproxen or other NSAID
• History of substance abuse including alcohol, or any psychiatric condition that may impair the subject's ability to comply with the study requirements.
• Any medical condition that, in the opinion of the investigator, might put the subject at undue risk or might interfere with the subject's ability to participate in the study.
• Participation in another clinical trial within 30 days or 7 half lives of the study agent, whichever is longer, of the screening visit.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: flavocoxid 500 mg; flavonoid mixture	Dietary supplement: flavocoxid; medical food; Other Names: Limbrel
Active Comparator: naproxen; nonsteroidal anti-inflammatory drug	Drug: Naproxen; antiinflammatory drug; Other Names: naprosyn

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Western Ontario and McMaster Universities Arthritis (WOMAC) Composite Score: Percent Change From Baseline to Week 12.	WOMAC is a composite of subscales: pain - 5 questions, stiffness - 2 questions, physical function - 17 questions. Subject answers each question as none=0, slight=1, moderate=2, very=3 and extreme=4 of pain, stiffness and difficulty of function. Scores for each subscale are summed, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Individual question scores are then summed to form a raw score ranging from 0 (worst) to 96 (best). Raw scores are normalized by multiplying each score by 100/96. This produces a reported WOMAC Score of between 0 (worst) to 100 (best).The higher the score of the units on the scale, the better the outcome. For each individual subject, the percent change from baseline to Week 12 in the WOMAC composite score is calculated as 100 x (week 12 minus baseline)/baseline. The higher the percent change, the better the outcome. The percent changes from baseline to Week 12 are then compared between Flavocoxid and Naproxen.	As measured at Baseline and Week 12

Collaborators and Investigators

• Sponsor: Primus Pharmaceuticals
• Investigators: Study Director: Paul H Caldron, DO, FACP, AmeRuss Clinical Trials LLC, USA

Study record dates

Study Major Dates

• Study Start: January 1, 2008
• Primary Completion (Actual): August 1, 2008
• Study Completion (Actual): August 1, 2008

Study Registration Dates

• First Submitted: January 16, 2008
• First Submitted That Met QC Criteria: November 13, 2008
• First Posted (Estimate): November 14, 2008

Study Record Updates

• Last Update Posted (Actual): November 1, 2022
• Last Update Submitted That Met QC Criteria: October 6, 2022
• Last Verified: October 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Gout Suppressants; Naproxen
• Other Study ID Numbers: LOA-04P

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: interested researchers may contact sponsor